Drug Trial Radar · NCT06151574
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
428
Actual
Start
Feb 9, 2024
Primary completion
Dec 10, 2026
Study completion Jan 28, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein. Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
Conditions
- Lung Cancer, Non-squamous, Non-small Cell
Interventions
zongertinibDrug
zongertinib
pembrolizumabDrug
pembrolizumab
cisplatinDrug
platinum-pemetrexed chemotherapy
carboplatinDrug
platinum-pemetrexed chemotherapy
pemetrexedDrug
platinum-pemetrexed chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent reviewTime frame: up to 4 years and 5 months
Locations
163 sites in 26 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
Pioneer Research Center - Bullhead City
Bullhead City, Arizona
Precision NextGen Oncology
Beverly Hills, California
ClinRé 001-022 (Premier Cancer Care and Infusion Center)
Fresno, California
OPN Healthcare, Inc.
Glendale, California
Scripps Green Hospital
La Jolla, California
Valkyrie Clinical Trials
Los Angeles, California
Sharp Memorial Hospital
San Diego, California
St. Louis Cancer Care, LLP
Bridgeton, Missouri
Oncology Hematology Associates
Springfield, Missouri
Cancer Care Specialists
Reno, Nevada
Northwell Health
Lake Success, New York
Montefiore Medical Center
The Bronx, New York
Regional Medical Oncology Center
Wilson, North Carolina
Gabrail Cancer Center
Canton, Ohio
Carolina Blood and Cancer Care Associates, PA
Rock Hill, South Carolina
SCRI Oncology Partners
Nashville, Tennessee
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists, PC
Fairfax, Virginia
Swedish Cancer Institute
Edmonds, Washington
Swedish Cancer Institute
Issaquah, Washington
Swedish Cancer Institute
Seattle, Washington
Clinica Adventista Belgrano
CABA, Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autónoma de Bs As, Argentina
Instituto Oncologico de Cordoba
Córdoba, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Argentina
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia
Royal North Shore Hospital-St Leonards-20807
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia
Krems University Hospital
Krems, Austria
Clinic Floridsdorf
Vienna, Austria
Brussels - HOSP Jules Bordet
Anderlecht, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Associacao Dr. Bartholomeu Tacchini
Bento Gonçalves, Brazil
Hospital do Câncer de Londrina
Londrina, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.